Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-13
2010-06-29
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07745455
ABSTRACT:
Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound is a new therapeutic anti HIV option, in combination with another drug such as a NRTI or a protease inhibitor. It's heightened and sustained antiretroviral potency is due to the increased intracellular level of 3TC triphosphate, the active form of 3TC. This effect is obtained by combining 3TC, in usual doses, with a reduced dose of ddC, in the same pharmaceutical formulation. The product could be administered twice or even once daily, which is convenient, and does not increase the pill burden for the patient. The reduced ddC dosage prevents the occurrence of ddC related side effects. Other cytidine derivatives (racemic or negative enantiomers) could have the same effects as ddC and could probably be combined with 3TC, and have the same effect. On the other hand, low dose ddC may also increase the intracellular levels of other cytidine derivatives as it does for 3TC. Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound could also be formulated in combination with another drug such as another NRTI (e.g. abacavir) or any protease inhibitor in the same capsule or tablet. This approach offers a dual anti-HIV therapy that is as efficacious as the routine triple therapy. In this way the HIV treatment cost could be significantly reduced which is imperative for resource-poor settings. This new formulation is convenient and well tolerated with no additional toxicity than that of the combining drug (NRTI or protease inhibitor) and 3TC. Moreover, this will enable a larger number of patients to benefit from the already known 3TC effects. It will also increase the 3TC effects in those organs or HIV sanctuaries with usually reduced 3TC concentrations or activity. It could be indicated in both the initial as well as in salvage HIV therapy. It could also be used for therapy optimization or simplification. Moreover, in combination with another NRTI such as abacavir, or even alone, it could be beneficial for reducing the HIV harm in resource-poor settings.
REFERENCES:
patent: 5028595 (1991-07-01), Soo
patent: WO96/23509 (1996-08-01), None
Dutschman, G.E. et al., Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-B-L(-)-5-Fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus B-D(+) nucleotide analogs in vitro, Antimicrobial Agents and Chemotherapy, 1998, 1799-1804, 42-7.
Hoggard, P.G., et al., Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro, Antivir Chem and Chemother, 2000, 353-358, 11.
Macher, A., et al., CME contraindicated antiretroviral drug combinations, New-Jersey Med., 2003, 41-43, 100-9.
Moyle, G. et al., Finding a role for zalcitabine in HAART era, Antiretroviral Therapy, 125-137, 3, (1998).
Sweeney, K.R., et al., Renal disposition and drug interaction screening of (-)-2′-deoxy-3′-thiacytidine (3TC) in the isolated perfused rat kidney, Phar Res, 1995, 1958-1963, 12-12.
Zapor, M.J., et al., Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors, 2004, 524-535, 45.
Diallo, K., et al., Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase, Antimicrob. Agents Chemother, 2003, 3377-3383, 47.
Gray, N.M., et al., The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ, Biochem Pharmacol, 1995, 1043-1051, 50-7.
Eron, J.J., et al., Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter, NEJM, 1995, 1661-1669, 333-25.
Veal, G.J., et al., Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation, AIDS, 1996, 546-548, 10-5.
Kewn, S., et al., Lamivudine (3TC) phosphorylation and drug interactions in vitro, Biochem Pharmacol, 1997, 589-595, 54.
Becher, F., et al., Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry, rapid commun mass spectrom, 2002, 555-565, 16-6.
UNAIDS/WHO, 2006 Report on the global AIDS epidemic. UNAIDS-Geneva, Switzerland, 2006.
Barrtlett, G. J., Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Apr. 7, 2005, Department of Health and Human Services (DHHS).
Baek Bong-Sook
Bereskin & Parr LLP / S.E.N.C.R.L., s.r.l.
Kwon Brian-Yong S
LandOfFree
Zalcitabine (ddC) boosted lamivudine (3TC) compositions for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Zalcitabine (ddC) boosted lamivudine (3TC) compositions for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Zalcitabine (ddC) boosted lamivudine (3TC) compositions for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4211045